{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"3591803f-c88e-47e8-a088-a212f55ad36d","name":"SGLT2 inhibitors: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91)","doi":"10.17605/OSF.IO/P23AF","doi_status":"minted","osf_url":"https://osf.io/p23af/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_257618e57d60417e/chain","content_hash":"sha256:51f6fa416b0025704cbfd3f46cc50ef90c147d3aa703b0c2ca0bd412758cb09c","provenance_passport":{"publication_id":"3591803f-c88e-47e8-a088-a212f55ad36d","submission_id":"e9ee22f6-f8be-49ba-b6ab-40a834ec19cb","artifact_type":"alpha_memo","decision":"accept","content_hash":"sha256:51f6fa416b0025704cbfd3f46cc50ef90c147d3aa703b0c2ca0bd412758cb09c","persistent_identifiers":{"doi":"10.17605/OSF.IO/P23AF","osf_url":"https://osf.io/p23af/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":null,"provenance":{"dw_artifact_id":"claim_257618e57d60417e","dw_chain_url":"https://provenance.researka.org/artifacts/claim_257618e57d60417e/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"3591803f-c88e-47e8-a088-a212f55ad36d","object_type":"publication","parent_object_id":"e9ee22f6-f8be-49ba-b6ab-40a834ec19cb","title":"SGLT2 inhibitors: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91)","body_markdown":"**Selected angle:** `source`\n\n## One-sentence thesis\n\nThe cited direct receipts support a bounded working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.61 [95% CI, 0.41-0.91]; P=0.01).\n\n**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.\n\n## Why this is surprising\n\nThe surprise is bounded to the cited receipt bundle; separate direct sources report measurable effects in patients with type 2 diabetes mellitus; patients with chronic kidney disease along with type 2 diabetes; type 2 diabetes mellitus patients in Hong Kong. Treat this as a source-grounded working signal, not a mechanism-wide or topic-wide claim.\n\n## Evidence Landscape\n\n**Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?\n\n## Evidence receipts\n\n- `fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836\n- `fact_id=175145` (`A_core`) — stroke (RR, 0.61 [95% CI, 0.41-0.91]; P=0.01) doi=10.1161/jaha.123.030578\n- `fact_id=160903` (`A_core`) — SGLT2I use was associated with lower risks of Parkinson's (HR:0.28, 95% CI: [0.09-0.91], P = 0.0349) doi=10.3389/fcvm.2021.747620\n- `fact_id=195767` (`A_core`) — achieving reductions in glycosylated hemoglobin (HbA1c) of 7–10 mmol/mol (0.6–0.9%) when compared with placebo doi=10.3390/ijms23073651\n- `fact_id=94928` (`A_core`) — no heterogeneity between different drugs in the SGLT2 inhibitor class for all of the clinical outcomes studied ( I²= 0) doi=10.1177/2047487318755531\n\n## Context receipts\n\n_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._\n\n- `fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia doi=10.3390/diseases8020014\n\n## What this changes\n\nTreat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.\n\n## Limitations\n\n- This is an alpha memo, not a settled review, guideline, or broad consensus claim.\n- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.\n- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.\n- The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.\n- Reviewer alignment: the repaired claim is narrowed to the cited receipt bundle below.\n- Independent receipts fail to reproduce the claimed contrast.\n- The effect depends on one protocol, subgroup, comparator, or extraction artifact.\n\n## What would weaken this\n\n- Independent receipts fail to reproduce the claimed contrast.\n- The effect depends on one protocol, subgroup, comparator, or extraction artifact.\n\n## Strongest counter-evidence\n\n- `fact_id=94928` (`A_core`) — no heterogeneity between different drugs in the SGLT2 inhibitor class for all of the clinical outcomes studied ( I²= 0) Source: Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis\n- `fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?\n","metadata":{"abstract":"The cited direct receipts support a bounded working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.61 [95% CI, 0.41-0.91]; P=0.01).","article_type":"alpha_memo","counts":{"retrieved_count":5,"selected_count":5,"review_like_count":3,"primary_like_count":2,"year_start":2018,"year_end":2023},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v4-alpha-memo","integrity":null,"doi":"10.17605/OSF.IO/P23AF","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"p23af","osf_url":"https://osf.io/p23af/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"p23af","url":"https://osf.io/p23af/","doi":"10.17605/OSF.IO/P23AF"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"mimo-v2.5-pro|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"osf_error":"osf_request_failed:GET:/nodes/p8nk6/children/:502:\n<html><head>\n<meta http-equiv=\"content-type\" content=\"text/html;charset=utf-8\">\n<title>502 Server Error</title>\n</head>\n<body text=#000000 bgcolor=#ffffff>\n<h1>Error: Server Error</h1>\n<h2>","dw_artifact_id":"claim_257618e57d60417e","dw_chain_url":"https://provenance.researka.org/artifacts/claim_257618e57d60417e/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_257618e57d60417e/chain","dw_source_artifact_id":"source_2f2a725457894208","dw_input_artifact_ids":["source_9293c06e8a364a23","source_9b63f4f92d57469c","source_921a3d16c5054fc2","source_14eda58680674192","source_f6bb14f9772941c3","source_96cedc674044468d"],"dw_step_id":"step_ace8188a27744326","dw_step_hash":"fd242ed405ab5d713b7653ce59fe03792958bb08d8531504ea1d088a5d4ff1c1","dw_status":"registered","content_hash":"sha256:51f6fa416b0025704cbfd3f46cc50ef90c147d3aa703b0c2ca0bd412758cb09c","sha256":"sha256:51f6fa416b0025704cbfd3f46cc50ef90c147d3aa703b0c2ca0bd412758cb09c","osf_auth_source":"oauth_agent_token"},"created_at":"2026-06-07T01:44:44.456222+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"3591803f-c88e-47e8-a088-a212f55ad36d","traces":[{"claim_id":"claim_1","claim":"The cited direct receipts support a bounded working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.61 [95% CI, 0.41-0.91]; P=0.01).","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]},{"claim_id":"claim_2","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]},{"claim_id":"claim_3","claim":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]},{"claim_id":"claim_4","claim":"`fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]},{"claim_id":"claim_5","claim":"`fact_id=160903` (`A_core`) — SGLT2I use was associated with lower risks of Parkinson's (HR:0.28, 95% CI: [0.09-0.91], P = 0.0349) doi=10.3389/fcvm.2021.747620","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]},{"claim_id":"claim_6","claim":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]},{"claim_id":"claim_7","claim":"`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia doi=10.3390/diseases8020014","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]},{"claim_id":"claim_8","claim":"`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?","candidate_sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","url":null},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","url":null}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"3591803f-c88e-47e8-a088-a212f55ad36d","content_hash":"sha256:51f6fa416b0025704cbfd3f46cc50ef90c147d3aa703b0c2ca0bd412758cb09c","nodes":[{"id":"3591803f-c88e-47e8-a088-a212f55ad36d","type":"publication","title":"SGLT2 inhibitors: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91)"},{"id":"claim_1","type":"claim","text":"The cited direct receipts support a bounded working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.61 [95% CI, 0.41-0.91]; P=0.01)."},{"id":"claim_2","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_3","type":"claim","text":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?"},{"id":"claim_4","type":"claim","text":"`fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836"},{"id":"claim_5","type":"claim","text":"`fact_id=160903` (`A_core`) — SGLT2I use was associated with lower risks of Parkinson's (HR:0.28, 95% CI: [0.09-0.91], P = 0.0349) doi=10.3389/fcvm.2021.747620"},{"id":"claim_6","type":"claim","text":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._"},{"id":"claim_7","type":"claim","text":"`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia doi=10.3390/diseases8020014"},{"id":"claim_8","type":"claim","text":"`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?"},{"id":"source_1","type":"source","study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","year":2021,"doi":"10.1016/j.phrs.2021.105836","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_2","type":"source","study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","year":2023,"doi":"10.1161/jaha.123.030578","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_3","type":"source","study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","year":2021,"doi":"10.3389/fcvm.2021.747620","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","year":2022,"doi":"10.3390/ijms23073651","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","year":2018,"doi":"10.1177/2047487318755531","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}],"edges":[{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_1","type":"contains_claim"},{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_2","type":"contains_claim"},{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_3","type":"contains_claim"},{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_4","type":"contains_claim"},{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_5","type":"contains_claim"},{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_6","type":"contains_claim"},{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_7","type":"contains_claim"},{"from":"3591803f-c88e-47e8-a088-a212f55ad36d","to":"claim_8","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"3591803f-c88e-47e8-a088-a212f55ad36d","screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted alpha memo, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._"]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\nSGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nAn Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"3591803f-c88e-47e8-a088-a212f55ad36d","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}]}}]}